Undergoing percutaneous coronary intervention (PCI) for narrowed arteries with a novel bioadaptor has clinical non-inferiority and offers a significant reduction in adverse clinical events than a contemporary drug-eluting stent (DES), according to new data from the INFINITY-SWEDEHEART trial.